BlossomHill Therapeutics to Present at the 67th American Society of Hematology (ASH) Annual Meeting on Design of Phase 1/1b Study of BH-30236, an Oral Macrocyclic CLK Inhibitor, in R/R AML or HR-MDS
SAN DIEGO, Nov. 03, 2025 (GLOBE NEWSWIRE) — BlossomHill Therapeutics, Inc., a privately-held, clinical-stage biopharmaceutical company focused on the design and development of next-generation medicines for cancer, today announced an upcoming poster presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition, being held December 6-9, 2025 in Orlando, FL. The trial-in-progress […]